

FOR PARTIAL-ONSET SEIZURES

ARE LONG TITRATION PERIODS AFFECTING **YOUR PATIENTS?**

See how Oxtellar XR may help simplify
the dosing regimen for your patients with
partial-onset seizures.

Not actual patients.

INDICATION

Oxtellar XR® is indicated for the treatment of partial-onset seizures in patients 6 years of age and older.

CONTRAINDICATIONS

Oxtellar XR is contraindicated in patients with a known hypersensitivity to oxcarbazepine, or to any of the components of Oxtellar XR, or to eslicarbazepine acetate. Reactions have included anaphylaxis and angioedema.

ONCE-DAILY

Oxtellar XR®
(oxcarbazepine) extended-release tablets
600 mg 300 mg 150 mg

Please refer to the Important Safety Information on [page 3](#) and the full [Prescribing Information](#) for complete information on Oxtellar XR, or visit www.OxtellarXRhcp.com.



1 WEEK

to the recommended daily dose in adults¹

You and your patients shouldn't have to settle for a lengthy titration process.

With a once-daily dosing regimen, Oxtellar XR is designed to provide a convenient titration for your patients.

See why these patients switched to Oxtellar XR[®] (oxcarbazepine) extended-release tablets



Megan, 32 Oxtellar XR patient.

- Struggled with taking medication multiple times a day
- Experienced debilitating dizziness on previous medication
- Cycled through multiple treatments and doesn't want to wait for relief



Elijah, 11 Not actual patient.

- Took other AED twice daily but continued to have breakthrough partial-onset seizures
- Is a middle school student whose parents were concerned about the frequency with which he must take his medication
- His parents were also worried about the impact of his treatment during the school day

Oxtellar XR (oxcarbazepine) extended-release tablets for oral use

INDICATION

Oxtellar XR® is indicated for the treatment of partial-onset seizures in patients 6 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- Oxtellar XR is contraindicated in patients with a known hypersensitivity to oxcarbazepine, or to any of the components of Oxtellar XR, or to eslicarbazepine acetate. Reactions have included anaphylaxis and angioedema.

WARNINGS & PRECAUTIONS

- Clinically significant hyponatremia (sodium <125 mmol/L) may develop during treatment. Measurement and laboratory tests of serum sodium concentrations should be considered for patients during maintenance treatment with Oxtellar XR, particularly if the patient is receiving other medications known to decrease serum sodium levels. Discontinuation of oxcarbazepine treatment may be clinically required.
- Rare cases of anaphylaxis and angioedema involving the larynx, glottis, lips, and eyelids have been reported in patients after taking the first or subsequent doses of oxcarbazepine. Angioedema associated with laryngeal edema can be fatal. If a patient develops any of these reactions after treatment with Oxtellar XR, the drug should be discontinued and an alternative treatment started. Do not rechallenge these patients with Oxtellar XR.
- Approximately 25% to 30% of patients who have had hypersensitivity reactions to carbamazepine will experience hypersensitivity reactions with Oxtellar XR. Patients with a history of hypersensitivity reactions to carbamazepine should ordinarily be treated with Oxtellar XR only if the potential benefit justifies the potential risk. Discontinue Oxtellar XR immediately if signs or symptoms of hypersensitivity develop.
- Serious dermatological reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported in association with oxcarbazepine use. Should a patient develop a skin reaction while using Oxtellar XR, consideration should be given to discontinuing its use. (Please see WARNINGS section of complete prescribing information.)
- Anyone considering prescribing Oxtellar XR must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which antiepileptic drugs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during Oxtellar XR treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.
- Withdrawal of Oxtellar XR should be done gradually to minimize the potential of increased seizure frequency and status epilepticus.
- Multi-organ hypersensitivity reactions have occurred in patients on oxcarbazepine therapy. Some of these cases resulted in hospitalization and some were life-threatening. Signs and symptoms of this disorder were diverse; however, patients typically, although not exclusively, presented with fever and rash associated with other organ system involvement disorders. If an alternative etiology cannot be established, discontinue Oxtellar XR.
- Rare reports of hematologic events such as pancytopenia, agranulocytosis, and leukopenia have been seen in patients treated with oxcarbazepine and discontinuation of therapy should be considered if any evidence of these hematologic events develop.
- Due to physiological changes during pregnancy, plasma concentrations of the active metabolite of oxcarbazepine may gradually decrease throughout pregnancy. An increase in seizure frequency may occur. Monitor patients carefully during pregnancy and through the postpartum period.
- Exacerbation of or new onset primary generalized seizures has been reported with immediate-release oxcarbazepine. The risk is seen especially in children, but may also occur in adults. Discontinue Oxtellar XR if it occurs.
- Data on a limited number of pregnancies from pregnancy registries suggest that oral clefts and ventricular septal defects are associated with oxcarbazepine monotherapy use.

DOSING CONSIDERATIONS

- Enzyme inducing antiepileptic drugs such as carbamazepine, phenobarbital, and phenytoin decrease the exposure to MHD, the active metabolite of Oxtellar XR. Dosage increases or discontinuation of enzyme inducers may be necessary.
- In adult patients with severe renal impairment, initiate Oxtellar XR at a lower starting dose and increase, if necessary, at a slower than usual rate until the desired clinical response is achieved.
- Use of Oxtellar XR with certain hormonal contraceptives may decrease hormone plasma levels and render these contraceptives less effective. Additional or alternative non-hormonal forms of contraception are recommended.

ADVERSE REACTIONS

The most commonly observed adverse reactions ($\geq 5\%$ and more frequent than placebo) seen in adults were (1200 mg, 2400 mg, v placebo): dizziness (20%, 41%, v 15%), somnolence (12%, 14%, v 9%), headache (8%, 15%, v 7%), balance disorder (5%, 7%, v 5%), tremor (5%, 1%, v 2%), vomiting (6%, 15%, v 9%), diplopia (10%, 13%, v 4%), asthenia (3%, 7%, v 1%), and fatigue (6%, 3%, v 1%). Adverse reactions in pediatric patients are similar to those seen in adults.

Please refer to the full [Prescribing Information](#) for complete information on Oxtellar XR.

Consider a proven, once-daily option with a convenient titration schedule

Adult Patients¹

- Initiate treatment at a dosage of 600 mg/day given orally once daily for 1 week. Subsequent dosage increases can be made at weekly intervals in 600 mg/day increments¹
- Maintain at 1200 mg/day to 2400 mg/day once daily¹
- For patients who require the 2400 mg/day dose, titration takes 2 weeks

1 WEEK
to 1200 mg/day
once-daily maintenance dose in adults¹



Tablets shown are not actual size.

Pediatric Patients (aged 6 to <17 years)¹

- Initiate with 8 mg/kg to 10 mg/kg once per day. Titrate to target dose over 2 to 3 weeks. Increase in weekly increments of 8 mg/kg to 10 mg/kg once daily, not to exceed 600 mg, to achieve target daily dose

TARGET DAILY DOSE	WEIGHT
900 mg/day	20 to 29 kg
1200 mg/day	29.1 to 39 kg
1800 mg/day	Greater than 39 kg

Geriatric Patients¹:

Start at a lower dosage (300 mg/day or 450 mg/day). Subsequent dosage increases can be made at weekly intervals in increments of 300 mg to 450 mg/day to achieve the desired clinical effect



“The ease of titration is very important for patients. If it's too complicated or long, we have the risk of breakthrough partial-onset seizures, or patients that are not able to follow that titration. With Oxtellar XR, it's a very simplistic process.”

Monali Patel, MD

Division of Neurology

SENTA Medical Center, San Diego, CA



Administering Oxtellar XR¹:



- **Patients should take Oxtellar XR on an EMPTY STOMACH at least 1 hour before or at least 2 hours after meals**
- Oxtellar XR tablets should be swallowed whole. Do not cut, crush, or chew the tablets
- Lower-strength tablets (150 mg tablets) are available for pediatric patients or patients with difficulty swallowing
- For patients previously treated with oxcarbazepine, higher doses of Oxtellar XR may be necessary
- Enzyme inducing antiepileptic drugs such as carbamazepine, phenobarbital, and phenytoin decrease the exposure to MHD, the active metabolite of Oxtellar XR. Dosage increases or discontinuation of enzyme inducers may be necessary
- In patients with severe renal impairment, initiate Oxtellar XR at a lower starting dose and increase, if necessary, at a slower than usual rate until the desired clinical response is achieved
- Use of Oxtellar XR with certain hormonal contraceptives may decrease hormone plasma levels and render these contraceptives less effective. Additional or alternative non-hormonal forms of contraception are recommended

Help simplify your patient's dosing regimen with Oxtellar XR.

- **Convenient** titration schedule
- **Effective** once-daily dosing
- **Easy** online ordering



Not actual patients.

Order samples online with no patient info needed



Get started at www.OxtellarXRhcp.com
or use your mobile device to scan the QR code.

ONCE-DAILY
Oxtellar XR.
(oxcarbazepine) extended-release tablets
600 mg 300 mg 150 mg

INDICATION

Oxtellar XR® is indicated for the treatment of partial-onset seizures in patients 6 years of age and older.

CONTRAINDICATIONS

Oxtellar XR is contraindicated in patients with a known hypersensitivity to oxcarbazepine, or to any of the components of Oxtellar XR, or to eslicarbazepine acetate. Reactions have included anaphylaxis and angioedema.

Reference:

1. Oxtellar XR. Package insert. Supernus Pharmaceuticals Inc.

Please refer to the Important Safety Information on [page 3](#) and the full [Prescribing Information](#) for complete information on Oxtellar XR, or visit www.OxtellarXRhcp.com.